Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319626 | 0.80 | DYRK1A (0.55) | IDO1MKNK1MKNK2DYRK1ASCN9A | |
| SCHEMBL13261852 | 0.80 | DYRK1A (0.42) | MKNK1MKNK2DYRK1A | |
| SCHEMBL30091450 | 0.80 | ABL1 (0.62) | ABL1DYRK1ASCN9AMAPK13MAPK12 | |
| SCHEMBL21859672 | 0.80 | ABL1 (0.62) | ABL1DYRK1ASCN9AMAPK13MAPK12 | |
| SCHEMBL10148612 | 0.80 | DYRK1A (0.58) | MKNK1MKNK2DYRK1AALOX5APFEN1 | |
| SCHEMBL31573684 | 0.80 | DYRK1A (0.41) | MKNK1MKNK2ABL1DYRK1ASCN9A | |
| SCHEMBL12804563 | 0.78 | IDO1 (0.44) | NPC1KDM1AIDO1ALOX5APFEN1 | |
| SCHEMBL1423495 | 0.77 | IDO1 (0.53) | NPC1IDO1MAPK13MAPK12MAPK11 | |
| SCHEMBL3363019 | 0.77 | PIK3C3 (0.47) | DYRK1AALOX5APFEN1SCN9AMAPK13 | |
| SCHEMBL23717672 | 0.76 | NOS3 (0.45) | MKNK1MKNK2ABL1DYRK1AALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109667-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | NPC1 1469/4885KDM1A 1988/4885IDO1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.